Subcutaneous EEG: Forecasting of Epileptic Seizures
Launched by KING'S COLLEGE LONDON · Aug 16, 2019
Trial Information
Current as of May 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of treatment-resistant epilepsy of any syndrome, in which seizures are detectable in scalp EEG with two electrodes
- • Between the ages of 18 - 75
- • Experiencing \>20 seizures (with impaired awareness) per year according to seizure diary.
- Exclusion Criteria:
- • Established current diagnosis of psychogenic non-epileptic attacks (dissociative seizures)
- • Frequent vigorous involuntary movements (eg. chorea, athetosis) or frequent parasomnias with major motor components (eg. sleep walking, night terrors)
- • Inability to comply with the trial procedure, such as cognitive or behavioral problems
- • Inability to give informed consent
- • History or evidence of: Severe cardiac disease (including Pacemaker and ICD-unit), Myocardial infarction, angina pectoris or other ischaemic heart disease, Cardiac arrhythmia or Any other heart failure
- • History or evidence of: Stroke, Transient ischaemic attack, Carotid or vertebral artery stenosis or dissection, Cerebral hemorrhage, Any other structural cerebral disease
- • Use of following drugs: Chemotherapeutic drugs of any kind, Methotrexate, Anticoagulation treatment, Immunosuppressant treatment, Third generation antipsychotic drugs (aripiprazole, quetiapine, clozapine, ziprasidone, paliperidone, risperidone, sertindole, amisulpride, olanzapine)
- • Subjects under investigation or treatment of active cancer or cancer diagnosis within the past 5 years
- • Subjects known with or suspected abuse of alcohol (defined as consumption of \> 250g alcohol per week or abuse of any other neuro-active substances
- • Subjects involved in therapies with medical devices that deliver electrical energy into the area around the implant.
- • Subjects at high risk of surgical complications, such as active systemic infection and hemorrhagic disease.
- • Subjects who are allergic to the local anesthetics used during implantation.
- • Subjects whose safety blood measurements (full blood count, U\&E, clotting) are significantly out of range in the judgement of the CI.
- • Females of childbearing potential who are pregnant or intend to become pregnant or are not using adequate contraceptive methods throughout the study (Safe anticontraceptive methods includes contraceptive pills, intrauterine device including hormone intrauterine device and sustained gestagen injection)
- • Subjects who have an infection at the site of device implantation.
- • Subjects who operate MRI scanners or are planned to have an MRI scan within the next year.
- • Subjects with profession/hobby that includes activity imposing extreme pressure variations (e.g. diving or parachute jumping). NB: diving/snorkeling is allowed to 5 meters of depth.
- • Subjects with profession/hobby that includes activity imposing an unacceptable risk for trauma against the device or the site of implantation (e.g. martial art or boxing).
About King's College London
King's College London is a prominent research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the college leverages its extensive expertise in medicine, neuroscience, and public health to conduct rigorous studies aimed at improving patient outcomes. As a sponsor of clinical trials, King's College London prioritizes ethical standards, participant safety, and scientific integrity, fostering an environment that encourages groundbreaking research and the translation of findings into clinical practice. Through its state-of-the-art facilities and a diverse network of researchers, the institution strives to address critical health challenges and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Mark P Richardson, BM FRCP PhD
Principal Investigator
King's College London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials